Orchard Therapeutics plc American Depositary Shares
Compare this stock
ORTX Stock Report Card
$
53%
Performance
Score:
100/100
ORTX returned 259.97% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
Score:
81/100
4 analysts offer 12-month price targets for ORTX. Together, they have an average target of 0, the most optimistic target put ORTX at 0 within 12-months and the most pessimistic has ORTX at 0.
Sentiment
Score:
68/100
ORTX had a bullish sentiment score of 67.99% across Twitter and StockTwits over the last 12 months. It had an average of 8.49 posts, 3.18 comments, and 8.07 likes per day.
Technicals
Score:
86/100
ORTX receives a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.
Earnings
Score:
10/100
ORTX has missed earnings 10 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, ORTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
56/100
ORTX has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.
Orchard Therapeutics plc American Depositary Shares Summary
Nasdaq / ORTX
Healthcare
Biotechnology
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ORTX scored highly on our reportcard. Here are some similar companies and how they performed.
